Design and biological evaluation of triagonist GLP-1R/GCGR/GIPR peptides as potential therapeutic agents for diabetes and obesity

Authors:

Abstract
Rational design and molecular modelling enabled the development of potent GLP-1/GIP/GCGR triagonists with robust in vitro activity and efficacy comparable to established incretin agonists.
Funding Information
  • Narodowe Centrum Badań i Rozwoju (POIR.01.01.01-00-0215/20)

This publication has 36 references indexed in Scilit: